```
=> d his full

     (FILE 'HOME' ENTERED AT 17:05:32 ON 14 OCT 2005)

     FILE 'HCAPLUS' ENTERED AT 17:05:38 ON 14 OCT 2005
L1            2 SEA ABB=ON  PLU=ON  (US2003158101 OR US5990077)/PN OR (US2002-0
                42746# OR US96-632533# OR US95-422540#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 17:07:13 ON 14 OCT 2005

     FILE 'HCAPLUS' ENTERED AT 17:07:13 ON 14 OCT 2005
L2              TRA L1 1- RN :       14 TERMS

     FILE 'REGISTRY' ENTERED AT 17:07:13 ON 14 OCT 2005
L3           14 SEA ABB=ON  PLU=ON  L2

     FILE 'WPIX' ENTERED AT 17:07:34 ON 14 OCT 2005
L4            5 SEA ABB=ON  PLU=ON  (US2003158101 OR US5990077)/PN OR (US2002-0
                42746# OR US96-632533# OR US95-422540#)/AP,PRN

=> b hcap
FILE 'HCAPLUS' ENTERED AT 17:08:02 ON 14 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Oct 2005  VOL 143 ISS 17
FILE LAST UPDATED: 13 Oct 2005  (20051013/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all l1 tot

L1   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2001:91506  HCAPLUS
DN   134:168296
ED   Entered STN:  07 Feb 2001
TI   Intestinotrophic glucagon-like peptide-2 analogs
IN   Drucker, Daniel J.; Crivici, Anna E.; Sumner-Smith, Martin
PA   NPS Allelix Corp., Can.
SO   U.S., 16 pp., Cont.-in-part of U.S. Ser. No. 631,273, abandoned.
     CODEN: USXXAM
DT   Patent
LA   English
IC   ICM  A61K038-26
     ICS  A61K038-17; C07K014-605
INCL 514012000
CC   63-3 (Pharmaceuticals)
     Section cross-reference(s): 2
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    --------------------   --------
```

PI	US 6184201	B1	20010206	US 1997-835538	19970408 <--
	US 5990077	A	19991123	US 1995-422540	19950414 <--
	US 5789379	A	19980804	US 1996-669791	19960628 <--
	US 5834428	A	19981110	US 1996-669790	19960628 <--
	US 2001021767	A1	20010913	US 2001-764070	20010119 <--
	EP 1231219	A1	20020814	EP 2001-129072	20011207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 2003162703	A1	20030828	US 2002-293941	20021114 <--
	US 2003158101	A1	20030821	US 2002-42746	20021120 <--
PRAI	US 1995-422540	A2	19950414 <--		
	US 1996-631273	B2	19960412		
	US 1996-632533	B2	19960412 <--		
	US 1997-835538	A3	19970408		
	US 2001-764070	A1	20010119		
	EP 1997-916280	A3	20011207		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 6184201	ICM	A61K038-26	
	ICS	A61K038-17; C07K014-605	
	INCL	514012000	
US 6184201	NCL	514/012.000; 424/009.200; 514/002.000; 514/003.000; 530/303.000; 530/308.000; 530/324.000	
	ECLA	C07K014/605	<--
US 5990077	NCL	514/002.000; 514/003.000; 514/012.000; 530/303.000; 530/308.000; 530/324.000	
	ECLA	C07K014/605	<--
US 5789379	NCL	514/012.000; 435/366.000; 435/371.000; 514/002.000; 514/003.000; 530/303.000; 530/308.000; 530/324.000	
	ECLA	C07K014/605	<--
US 5834428	NCL	514/012.000; 435/366.000; 435/371.000; 514/002.000; 514/003.000; 530/303.000; 530/308.000; 530/324.000	
	ECLA	C07K014/605	<--
US 2001021767	NCL	530/320.000	
	ECLA	C07K014/605	<--
EP 1231219	ECLA	C07K014/605	
US 2003162703	NCL	514/012.000	
	ECLA	C07K014/605	<--
US 2003158101	NCL	514/012.000	
	ECLA	C07K014/605	<--

OS MARPAT 134:168296

AB Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceuticals and therapeutic use in treating disorders of the small bowel are described.

ST glucagon like peptide 2 analog intestine therapy sequence

IT Intestine, disease
(Crohn's; intestinotrophic glucagon-like peptide-2 analogs)

IT Drug delivery systems
(carriers; intestinotrophic glucagon-like peptide-2 analogs)

IT Digestive tract
(disease; intestinotrophic glucagon-like peptide-2 analogs)

IT Intestine, disease
(enteritis; intestinotrophic glucagon-like peptide-2 analogs)

IT Digestive tract
(indigestion; intestinotrophic glucagon-like peptide-2 analogs)

IT Intestine, disease
(inflammatory; intestinotrophic glucagon-like peptide-2 analogs)

IT Chemotherapy
(intestinal damage from; intestinotrophic glucagon-like peptide-2 analogs)

IT Antiulcer agents
Celiac disease
Drug delivery systems
Protein sequences

Ulcer
(intestinotrophic glucagon-like peptide-2 analogs)
IT Intestine, disease
(malabsorption; intestinotrophic glucagon-like peptide-2 analogs)
IT Intestine, disease
(short bowel syndrome; intestinotrophic glucagon-like peptide-2 analogs)
IT Intestine, disease
(small; intestinotrophic glucagon-like peptide-2 analogs)
IT Digestive tract
(sprue; intestinotrophic glucagon-like peptide-2 analogs)
IT 54249-88-6, Dipeptidyl peptidase IV
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(intestinotrophic glucagon-like peptide-2 analogs)
IT 89750-15-2D, Glucagon-like peptide 2, analogs
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(intestinotrophic glucagon-like peptide-2 analogs)
IT 223460-79-5, 1-33-Glucagon-like peptide II (human) 325150-06-9
325150-33-2
RL: PRP (Properties)
(unclaimed protein sequence; intestinotrophic glucagon-like peptide-2 analogs)
IT 81156-22-1
RL: PRP (Properties)
(unclaimed sequence; intestinotrophic glucagon-like peptide-2 analogs)
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Allen; US 4920016 1990 HCAPLUS
(2) Anon; EP 0612531 1994 HCAPLUS
(3) Baumann; US 5009956 1991 HCAPLUS
(4) Cheeseman; "The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal basolateral membrane hexose transport", APSracts 3:0071G 1996
(5) Cullis; US 5008050 1991 HCAPLUS
(6) Drucker; US 5789379 1998 HCAPLUS
(7) Drucker; US 5990077 1998 HCAPLUS
(8) Ehrlich; American Journal of Physiology 1994, PE662 HCAPLUS
(9) Evans; US 4311712 1982 HCAPLUS
(10) Evans; US 4370349 1983 HCAPLUS
(11) George; FEBS Letters 1985, V192(2), P275 HCAPLUS
(12) Gersonde; US 4452747 1984 HCAPLUS
(13) Haynes; US 4725442 1988 HCAPLUS
(14) Hunt; US 4529561 1985 HCAPLUS
(15) Irwin; Molecular Endocrinology 1995, V9, P267 HCAPLUS
(16) Kodama; US 4372949 1983 HCAPLUS
(17) Lund; Digestion 1993, P371
(18) Martin; US 4737323 1988
(19) Mommsen; FEBS Letters 1987, V219(1), P227 HCAPLUS
(20) Morano; US 4927637 1990
(21) Nishi; Molecular Endocrinology 1990, V4, P1192 HCAPLUS
(22) Orskov; Diabetologia 1987, V30, P874 MEDLINE
(23) Orskov; FEBS Letters 1989, V247(2), P193 MEDLINE
(24) Roberts; US 4921706 1990
(25) Ruiz-Grande; Can J Physiology Pharmacology 1990, V68(12), P1568 HCAPLUS
(26) Shennan; Molecular and Cellular Endocrinology 1989, V67, P93 HCAPLUS
(27) Suzuki; US 4016100 1977 HCAPLUS
(28) Uster; US 4944948 1990 HCAPLUS
(29) Watanabe; Biochemical and Biophysical Research Communications 1988, V152(3), P1038 HCAPLUS

L1 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:756228 HCAPLUS
DN 126:19330
ED Entered STN: 26 Dec 1996

TI Preparation of glucagon-like peptide-2 analogs as as gastrointestinal tissue growth factors
IN Drucker, Daniel J.
PA 1149336 Ontario Inc., Can.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-605
ICS A61K038-26
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9632414	A1	19961017	WO 1996-CA232	19960412	<--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML					
	US 5990077	A	19991123	US 1995-422540	19950414	<--
	CA 2218225	AA	19961017	CA 1996-2218225	19960412	<--
	AU 9652658	A1	19961030	AU 1996-52658	19960412	<--
	AU 720493	B2	20000601			
	EP 830377	A1	19980325	EP 1996-908973	19960412	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	CN 1188485	A	19980722	CN 1996-194693	19960412	<--
	JP 11505521	T2	19990521	JP 1996-530606	19960412	<--
	AU 753771	B2	20021031	AU 2001-65566	20010830	<--
PRAI	US 1995-422540	A	19950414	<--		
	WO 1996-CA232	W	19960412			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 9632414	ICM	C07K014-605	
	ICS	A61K038-26	
WO 9632414	ECLA	C07K014/605	<--
US 5990077	NCL	514/002.000; 514/003.000; 514/012.000; 530/303.000; 530/308.000; 530/324.000	
	ECLA	C07K014/605	<--

OS MARPAT 126:19330
AB Glucagon-like peptide-2, a product of glucagon gene expression, and analogs of glucagon-like peptide-2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation as a pharmaceutical, and their therapeutic use in treating disorders of the bowel, are described. Thus, rat glucagon-like peptide-2, prepared by standard solid-phase methods using Boc chemical on a 4-methylbenzhydrylamine (MBHA) resin, administered for 10 days, stimulated villus elongation in CD1 mice small bowel. Proliferation rates in the proximal jejunum of the treated mice were increased 124% over control mice.
ST glucagon like peptide prepn gastrointestinotrophic; small bowel growth glucagon like peptide; pancreatic islet growth glucagon like peptide
IT Digestive tract
(disease; preparation of glucagon-like peptide-2 analogs as as gastrointestinal tissue growth factors)
IT Pancreatic islet of Langerhans
(preparation of glucagon-like peptide-2 analogs as as gastrointestinal tissue growth factors)
IT Intestine
(small; preparation of glucagon-like peptide-2 analogs as as gastrointestinal tissue growth factors)
IT 89750-15-2P, Glucagon-related peptide-II

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(degu; preparation of glucagon-like peptide-2 analogs as as gastrointestinal tissue growth factors)

IT 93927-39-0P, Glucagon-related peptide II (rat) 99120-49-7P, Glucagon-like peptide II (human) 107444-51-9P 184378-22-1P 184378-24-3P 184378-25-4P 184378-26-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glucagon-like peptide-2 analogs as as gastrointestinal tissue growth factors)

IT 71567-77-6, Glicentin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rat; preparation of glucagon-like peptide-2 analogs as as gastrointestinal tissue growth factors)

=> b reg;d sqide l3 tot
FILE 'REGISTRY' ENTERED AT 17:08:17 ON 14 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 OCT 2005 HIGHEST RN 865114-63-2
DICTIONARY FILE UPDATES: 12 OCT 2005 HIGHEST RN 865114-63-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

L3 ANSWER 1 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **325150-33-2** REGISTRY
CN 3: PN: US6184201 SEQID: 3 unclaimed protein (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 5

NTE

type	location		description
uncommon	Aaa-2	-	-

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US6184201 unclaimed SEQID 3

SEQ 1 EXNTI

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **325150-06-9** REGISTRY
CN 1: PN: US6184201 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 37
NTE

type	location		description
uncommon	Aaa-1	-	-
uncommon	Aaa-2	-	-
uncommon	Aaa-3	-	-
uncommon	Aaa-4	-	-
uncommon	Aaa-5	-	-
uncommon	Aaa-6	-	-
uncommon	Aaa-11	-	-
uncommon	Aaa-12	-	-
uncommon	Aaa-13	-	-
uncommon	Aaa-14	-	-
uncommon	Aaa-15	-	-
uncommon	Aaa-21	-	-
uncommon	Aaa-22	-	-
uncommon	Aaa-25	-	-
uncommon	Aaa-26	-	-
uncommon	Aaa-33	-	-
uncommon	Aaa-34	-	-
uncommon	Aaa-35	-	-
uncommon	Aaa-36	-	-
uncommon	Aaa-37	-	-

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US6184201 unclaimed SEQID 1

```
SEQ      1 XXXXXXSFSD XXXXXLDNLA XXDFXXWLIQ TKXXXXX
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  PRP (Properties)
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3   ANSWER 3 OF 14  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   223460-79-5  REGISTRY
CN   1-33-Glucagon-like peptide II (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1: PN: US6297214 SEQID: 1 claimed protein
CN   1: PN: WO2004035624 FIGURE: 1 claimed protein
CN   2: PN: US6184201 SEQID: 2 unclaimed protein
CN   2: PN: WO2005019262 SEQID: 2 claimed protein
CN   6: PN: WO2005019262 SEQID: 2 claimed protein
CN   Glucagon-like peptide II (human)
CN   Human glucagon-like peptide-2
FS   PROTEIN SEQUENCE
SQL  33

PATENT ANNOTATIONS (PNTE):
Sequence |Patent
Source   |Reference
=========+==========
Not Given|US6184201
         |unclaimed
         |SEQID 2
---------+----------
         |US6297214
         |claimed
         |SEQID 1


SEQ      1 HADGSFSDEM NTILDNLAAR DFINWLIQTK ITD

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF   C165 H254 N44 O55 S
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PRP
       (Properties); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL (Biological
       study); PREP (Preparation); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP
       (Properties); USES (Uses)
              17 REFERENCES IN FILE CA (1907 TO DATE)
               2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3   ANSWER 4 OF 14  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   184378-26-5  REGISTRY
CN   L-Aspartic acid, L-arginyl-L-arginyl-L-histidyl-L-alanyl-L-α-
     aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-α-
     glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-
     α-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-threonyl-L-arginyl-L-
     α-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-
     leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-
```

(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 35

SEQ 1 RRHADGSFSD EMNTILDNLA TRDFINWLIQ TKITD
MF C178 H280 N52 O58 S
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **184378-25-4** REGISTRY
CN L-Aspartic acid, L-arginyl-L-histidyl-L-alanyl-L-α-aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-α-glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-threonyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 34

SEQ 1 RHADGSFSDE MNTILDNLAT RDFINWLIQT KITD
MF C172 H268 N48 O57 S
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **184378-24-3** REGISTRY
CN L-Aspartic acid, N-acetyl-L-histidyl-L-alanyl-L-α-aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-α-glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-threonyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 33
NTE modified

type	------ location ------		description
terminal mod.	His-1	-	N-acetyl

SEQ 1 HADGSFSDEM NTILDNLATR DFINWLIQTK ITD

RELATED SEQUENCES AVAILABLE WITH SEQLINK
DR 197923-52-7, 223460-86-4
MF C168 H258 N44 O57 S
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES

(Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)
3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 7 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **184378-22-1** REGISTRY
CN L-α-Asparagine, L-histidyl-L-alanyl-L-α-aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-α-glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-threonyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 33
NTE modified

type	------ location ------		description
terminal mod.	Asp-33	-	C-terminal amide

SEQ 1 HADGSFSDEM NTILDNLATR DFINWLIQTK ITD

RELATED SEQUENCES AVAILABLE WITH SEQLINK
DR 197923-54-9
MF C166 H257 N45 O55 S
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 8 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **107444-51-9** REGISTRY
CN L-Argininamide, L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glucagon-related peptide 1 (Rana catesbeiana), 3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-30-L-argininamide-31-de-L-proline-32-de-L-lysine-
OTHER NAMES:
CN (7-36)Glucagon-like peptide-1 amide
CN (7-36)Glucagon-like peptide-1 amide (human)
CN 13: PN: WO0041546 FIGURE: 3 claimed protein
CN 20: PN: WO2004069314 PAGE: 21 claimed protein
CN 36: PN: WO0155213 SEQID: 36 claimed sequence
CN 6: PN: WO2004005342 PAGE: 46 claimed protein
CN 7-36-Human glucagon-like peptide I amide
CN 774: PN: WO2004074315 SEQID: 775 claimed protein
CN Glucagon-like peptide-I(7-36) amide
CN Human GLP-1-(7-36)-amide
CN Human glucagon-like peptide-1-(7-36) amide
CN Insulinotropin
CN Insulinotropin (human)
CN Rat GLP-I(7-36)amide
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 30
NTE modified

type	location	description
terminal mod.	Arg-30 -	C-terminal amide

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2000041546 claimed FIGURE 3
	WO2001055213 claimed SEQID 36

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
DR 113789-12-1
MF C149 H226 N40 O45
CI COM
SR CA
LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CIN, CSCHEM, EMBASE, MEDLINE, PROMT, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 1-E



PAGE 2-B



PAGE 2-C



215 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
215 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **99120-49-7** REGISTRY
CN Glucagon-like peptide II (human) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glucagon-related peptide II (human)
OTHER NAMES:
CN 167: PN: WO0069900 SEQID: 346 unclaimed protein
CN L-Arginine, L-histidyl-L-alanyl-L-α-aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-α-glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L-α-aspartyl-
FS PROTEIN SEQUENCE
SQL 34

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2000069900 unclaimed SEQID 346

SEQ 1 HADGSFSDEM NTILDNLAAR DFINWLIQTK ITDR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
DR 123625-66-1, 104269-51-4
MF C171 H266 N48 O56 S
CI MAN
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); PRP (Properties)
29 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
29 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 10 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **93927-39-0** REGISTRY
CN Glucagon-like peptide II (rat) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glucagon-related peptide II (rat)
OTHER NAMES:
CN L-Lysine, L-histidyl-L-alanyl-L-α-aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-α-glutamyl-L-methionyl-L-

asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-threonyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L-α-aspartyl-L-lysyl-
FS PROTEIN SEQUENCE
SQL 35

SEQ 1 HADGSFSDEM NTILDNLATR DFINWLIQTK ITDKK
MF C178 H280 N48 O58 S
CI MAN
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process); PRP (Properties)
5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **89750-15-2** REGISTRY
CN Glucagon-like peptide II (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glucagon-related peptide II
OTHER NAMES:
CN Glucagon-like peptide 2
MF Unspecified
CI MAN
LC STN Files: ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CHEMCATS, CIN, IPA, MRCK*, PROMT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PROC (Process); PRP (Properties)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

333 REFERENCES IN FILE CA (1907 TO DATE)
34 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
333 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 12 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **81156-22-1** REGISTRY
CN L-Tyrosine, L-tyrosyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Tyrosine, N-[N2-(N-L-tyrosyl-L-seryl)-L-lysyl]-
OTHER NAMES:
CN 19: PN: US20040052862 SEQID: 8 unclaimed sequence
CN 4: PN: US6184201 SEQID: 4 unclaimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4

PATENT ANNOTATIONS (PNTE):
Sequence |Patent

Source	Reference
Not Given	US6184201
	unclaimed
	SEQID 5

SEQ 1 YSKY

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C27 H37 N5 O8
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: PRP (Properties)
RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.



5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **71567-77-6** REGISTRY
CN Glicentin (9CI) (CA INDEX NAME)
MF Unspecified
CI MAN
LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, DDFU, DRUGU, EMBASE, MEDLINE, PHAR, PROMT, TOXCENTER, USPATFULL
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PRP (Properties); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
169 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
169 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **54249-88-6** REGISTRY
CN Peptidase, dipeptidyl, IV (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1F7 antigens
CN Adenosine deaminase-binding proteins
CN Amino acyl-prolyl dipeptidyl aminopeptidase
CN Aminopeptidase, dipeptidyl, IV
CN Aminopeptidase, glycylproline
CN Aminopeptidase, post-proline dipeptidyl

CN Antigens, CD26
CN Casomorphinase
CN CD26 (antigen)
CN CD26 antigen
CN Dipeptidase-IV
CN Dipeptidyl peptidase 8
CN Dipeptidyl peptidase DP4
CN Dipeptidyl peptidase IV
CN Dipeptidyl peptidase-4
CN Dipeptidyl-aminopeptidase IV
CN Dipeptidyl-peptidase IV-β
CN DPP IV
CN E.C. 3.4.14.11
CN E.C. 3.4.14.5
CN EC 3.4.14.5
CN Gly-Pro naphthylamidase
CN Glycylproline aminopeptidase
CN Glycylproline-dipeptidyl-aminopeptidase
CN Glycylprolyl aminopeptidase
CN Glycylprolyl dipeptidylaminopeptidase
CN Post-proline dipeptidyl aminopeptidase
CN Post-proline dipeptidyl aminopeptidase IV
CN Prolyl dipeptidyl peptidase IV
CN X-Pro dipeptidyl peptidase
CN X-Prolyl dipeptidyl aminopeptidase
CN X-Prolyl dipeptidyl peptidase
CN X-Prolyl-dipeptidyl aminopeptidase
CN Xaa-Pro-dipeptidylaminopeptidase
DR 60241-40-9, 67339-10-0
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, EMBASE, IPA, PROMT, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2311 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2317 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b wpix;d all l4 tot
FILE 'WPIX' ENTERED AT 17:08:25 ON 14 OCT 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 14 OCT 2005 <20051014/UP>
MOST RECENT DERWENT UPDATE: 200566 <200566/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://thomsonderwent.com/coverage/latestupdates/ <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://thomsonderwent.com/support/userguides/ <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/
FOR DETAILS. <<<
'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

L4 ANSWER 1 OF 5 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2004-096715 [10] WPIX
CR 1996-477073 [47]; 1997-526401 [48]; 2001-217796 [22]; 2001-595776 [67];
2003-787348 [74]
DNC C2004-039903
TI New Glucagon-like peptide 2 analog with intestino-trophic activity, useful
for preparing a composition for treating gastrointestinal disease, e.g.
ulcers, malabsorption, short-gut syndrome and inflammatory bowel disease.
DC B04
IN CRIVICI, A E; DRUCKER, D J; SUMNER SMITH, M
PA (ALLX) NPS ALLELIX CORP
CYC 1
PI US 2003162703 A1 20030828 (200410)* 14 A61K038-28
ADT US 2003162703 A1 **CIP of US 1995-422540 19950414**, CIP of US
1996-631273 19960412, **CIP of US 1996-632533 19960412**, Div ex US
1997-835538 19970408, Cont of US 2001-764070 20010119, US 2002-293941
20021114
FDT US 2003162703 A1 CIP of US 5990077, Div ex US 6184201
PRAI US 1997-835538 19970408; **US 1995-422540**
19950414; US 1996-631273 19960412; **US**
1996-632533 19960412; US 2001-764070
20010119; US 2002-293941 20021114
IC ICM A61K038-28
ICS A61K038-00; A61K038-26; A61K049-00; C07K005-00; C07K007-00;
C07K016-00; C07K017-00
AB US2003162703 A UPAB: 20040210
NOVELTY - A Glucagon-like peptide 2 (GLP-2) analog that has
intestino-trophic activity and comprising formula (I), is new.
DETAILED DESCRIPTION - A Glucagon-like peptide 2 (GLP-2) analog that
has intestino-trophic activity and comprising formula (I), is new.
R1-(Y1)m-X1-X2-X3-X4-Ser5-Phe6-Ser7-Asp8-(P1)-Leu14-Asp15-Asn16-Leu17-
Ala18-X19-X20-Asp21-Phe22-(P2)-Trp25-Leu26-Ile27- Gln28-Thr29-Lys30-(P3)-
(Y2)n-R2 (I)
X1 = His or Tyr;
X2 = Ala or Ala-replacement amino acid conferring on the analog
resistance to DPP-IV enzyme;
X3 = Pro, Hpro, Asp or Glu;
X4 = Gly or Ala;
P1 = Glu-X10-Asn-Thr-Ile or Tyr-Ser-Lys-Tyr;
X10 = Met or an oxidatively stable Met-replacement amino acid;
X19 = Ala or Thr;
X20 = Arg, Lys, His or Ala;

P2 = Ile-Asn, Ile-Ala or Val-Gln;
P3 = covalent bond, or is Ile, Ile-Thr or Ile-Thr-Asn;
R1 = H or an N-terminal blocking group;
R2 = OH or a C-terminal blocking group;
Y1 or Y2 = one or two basic amino acids comprising Arg, Lys or His; and
m and n = independently, are 0 or 1.
At least one of X1, X2, X3, X4, P1, X10, X19, X20, P2 or P3 is other than a wild type, mammalian GLP-2 residue.
INDEPENDENT CLAIMS are also included for the following:
(1) a pharmaceutical composition comprising GLP-2 analog and a carrier;
(2) a method for promoting growth of small bowel tissue in a patient;
(3) a method for treating gastrointestinal disease; and
(4) a method of identifying intestino-trophic analogs of GLP-2.
ACTIVITY - Gastrointestinal; Antiinflammatory.
No biological data given.
MECHANISM OF ACTION - Gene therapy.
USE - The GLP-2 analog is useful for preparing a composition for treating gastrointestinal disease, e.g., ulcer, malabsorption, short-gut syndrome or cul-de-sac syndrome, inflammatory bowel disease, celiac or tropical sprue, regional enteritis or small intestine damage due to toxic or chemotherapeutic agents (claimed).
Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B04-C01F; B04-C01G; B11-C08E2; B12-K04E; B14-E08; B14-E10; B14-E10C; B14-S03

L4 ANSWER 2 OF 5 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2003-787348 [74] WPIX
CR 1996-477073 [47]; 1997-526401 [48]; 2001-217796 [22]; 2001-595776 [67]; 2004-096715 [10]
DNC C2003-217277
TI New pharmaceutical composition comprising a Glucagon-like peptide 2 (GLP-2) peptide comprising vertebrate GLP-2 or its intestinotrophic analog, useful for treating gastrointestinal disease, e.g., ulcers.
DC B04
IN DRUCKER, D J
PA (ONEO-N) 1149336 ONTARIO INC
CYC 1
PI US 2003158101 A1 20030821 (200374)* 25 A61K038-22 <--
ADT US 2003158101 A1 **CIP of US 1995-422540 19950414, Cont of US 1996-632533 19960412, US 2002-42746 20021120**
FDT US 2003158101 A1 CIP of US 5990077
PRAI **US 1996-632533 19960412; US 1995-422540 19950414; US 2002-42746 20021120**
IC ICM A61K038-22
AB US2003158101 A UPAB: 20040210
NOVELTY - A new pharmaceutical composition comprises a Glucagon-like peptide 2 (GLP-2) peptide comprising vertebrate GLP-2 or its intestinotrophic analog that differs from a vertebrate GLP-2 in that it incorporates at least one amino acid addition, deletion, substitution or an amino acid with an N- or C-terminal amino acid blocking group and a carrier.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a method for promoting growth of bowel tissue in a patient;
(2) a method for promoting growth of pancreatic islets in a patient;
(3) an acid addition salt of a GLP-2 peptide;
(4) a method for identifying novel intestinotrophic peptides; and
(5) a method for treating a gastrointestinal disease.
ACTIVITY - Gastrointestinal; Antiinflammatory. No biological data given.
MECHANISM OF ACTION - Gene therapy.
USE - The pharmaceutical composition is useful for treating

gastrointestinal disease comprising ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, enteritis, Crohn's disease or short bowel syndrome (claimed).
Dwg.0/9
FS CPI
FA AB; DCN
MC CPI: B04-C01G; B04-N04A; B11-C08E2; B14-C03; B14-E08; B14-E10C

L4 ANSWER 3 OF 5 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2001-595776 [67] WPIX
CR 1996-477073 [47]; 1997-526401 [48]; 2001-217796 [22]; 2003-787348 [74]; 2004-096715 [10]
DNC C2001-176363
TI Glucagon related peptides useful in the treatment of gastrointestinal diseases e.g. inflammatory bowel disease.
DC B04
IN CRIVICI, A E; DRUCKER, D J; SUMNER-SMITH, M
PA (CRIV-I) CRIVICI A E; (DRUC-I) DRUCKER D J; (SUMN-I) SUMNER-SMITH M
CYC 1
PI US 2001021767 A1 20010913 (200167)* 14 A61K038-18
ADT US 2001021767 A1 **CIP of US 1995-422540 19950414**, CIP of US 1996-631273 19960412, **CIP of US 1996-632533 19960412**, Div ex US 1997-835538 19970408, US 2001-764070 20010119
FDT US 2001021767 A1 CIP of US 5990077, Div ex US 6184201
PRAI US 1997-835538 19970408; **US 1995-422540 19950414**; US 1996-631273 19960412; **US 1996-632533 19960412**; US 2001-764070 20010119
IC ICM A61K038-18
AB US2001021767 A UPAB: 20040210
NOVELTY - Glucagon-related peptide analogs (I) with intestinotrophic activity are new.
DETAILED DESCRIPTION - Glucagon-related peptide (GLP-2) analogs of formula R1-(Y1)m-X1-X2-X3-X4-Ser5-Phe6-Ser7-Asp8-(P1)-Leu14-Asp15-Asn16-Leu17-Ala18-X19-X20-Asp21-Phe22-(P2)-Trp25-Leu26-Ile27-Gln28-Thr29-Lys30-(P3)-(Y2)n-R2 (I) are new.
X1 = His or Tyr;
X2 = Ala or Ala-replacement amino acid conferring on the analog resistance to Dipeptidyl peptidase (DPP-IV) enzyme;
X3 = Pro, HPro, Asp or Glu;
X4 = Gly or Ala;
P1 = Glu-X10-Asn-Thr-Ile or Tyr-Ser-Lys-Tyr;
X10 = Met or an oxidatively stable Met-replacement amino acid;
X19 = Ala or Thr;
X20 = Arg, Lys, His or Ala;
P2 = Ile-Asn, Ile-Ala or Val-Gln;
P3 = covalent bond, Ile, Ile-Thr or Ile-Thr-Asn;
R1 = H or N-terminal blocking group;
R2 = OH or C-terminal blocking group;
Y1, Y2 = 1 or 2 basic amino acids selected from Arg, Lys or His;
m, n = 0 or 1.
At least one of X1 - X4, P1, X10, X19, X20, P2 or P3 is other than a wild type, mammalian GLP-2 residue.
INDEPENDENT CLAIMS are also included for the following:
(A) a pharmaceutical composition comprising (I) and a carrier for promoting growth of small bowel tissue; and
(B) identifying intestinotrophic analogs of GLP-2 which involves:
(B1) obtaining (I)
(B2) treating a mammal (preferably rat) with a single regimen of (I), capable of eliciting an intestinotrophic effect; and
(B3) determining the effect of the analog on small bowel weight relative to a mock treated control mammal. The intestinotrophic analog of GLP-2 is identified as an analog which elicits an increase in the weight.
ACTIVITY - Antiulcer; Antiinflammatory.
MECHANISM OF ACTION - Dipeptidyl peptidase IV (DPP-IV) resistor.

A solution of human placental DPP-IV (2.5 mu l) containing enzyme (0.125 milliunits) in glycerol (50%), Tris (10 mM), EDTA (pH 7.8) and NaN3 (0.02%) was added to (Gly2)rGLP-2 analog (50 mu l), (D-Ala2)rGLP-2 analog (50 mu l) and a control peptide rGLP-2 (50 mu l) at a concentration of 0.2 mg/ml in phosphate buffered saline (PBS) at a pH of 7.4. The mixture was incubated at 37 deg. C for 24 hours. The incubation was quenched by the addition of a solution of diprotein A (50 mu l) in PBS. Each sample was analyzed by reverse phase HPLC. After 24 hours incubation, 22% of the control peptide was cleaved by DPP-IV. No cleavage products were detected for the peptides (Gly2)rGLP-2 and (D-Ala2)rGLP-2.

USE - In the treatment of gastrointestinal disease particularly ulcer, digestion disorder, malabsorption syndrome, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, enteritis, regional enteritis (Crohn's disease), small intestinal damage due to toxic or other chemotherapeutic agent, and short bowel syndrome (all claimed).

ADVANTAGE - The peptides show an increase in small bowel weight and promote growth of tissue of the small bowel.

Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B04-C01F; B04-C01G; B04-N04A; B11-C08E; B12-K04A; B14-E02; B14-E08; B14-E09; B14-E10C

L4 ANSWER 4 OF 5 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2001-217796 [22] WPIX
CR 1996-477073 [47]; 1997-526401 [48]; 2001-595776 [67]; 2003-787348 [74]; 2004-096715 [10]
DNC C2001-064901
TI Novel glucagon-like peptide 2 analog useful for promoting growth of small bowel tissue and for treating gastrointestinal disease such as ulcers, digestion disorders, malabsorption syndromes and cul-de-sac syndrome.
DC B04
IN CRIVICI, A E; DRUCKER, D J; SUMNER-SMITH, M
PA (ALLX) NPS ALLELIX CORP
CYC 1
PI US 6184201 B1 20010206 (200122)* 16 A61K038-26
ADT US 6184201 B1 **CIP of US 1995-422540 19950414**, CIP of US 1996-631273 19960412, **CIP of US 1996-632533 19960412**, US 1997-835538 19970408
FDT US 6184201 B1 CIP of US 5990077
PRAI US 1997-835538 19970408; **US 1995-422540 19950414**; US 1996-631273 19960412; **US 1996-632533 19960412**
IC ICM A61K038-26
ICS A61K038-17; C07K014-605
AB US 6184201 B UPAB: 20040210

NOVELTY - A glucagon-like peptide 2 (GLP-2) analog (I) or its salt, which has intestinotrophic activity, is new.

DETAILED DESCRIPTION - (I) has a formula (F) of R1-(Y1)m-X1-X2-X3-X4-Ser5-Phe6-Ser7-Asp8-(P1)-Leu14-Asp15-Asn16-Leu17-Ala18-X19-X20-Asp21-Phe22-(P2)-Trp25-Leu26-Ile27-Gln28-Thr29-Lys30-(P3)-(Y2)n-R2, where X1, X2, X3, X4, P1, X10, X19, X20, P2, P3, R1, R2, Y1, Y2, m and n are as defined in DEFINITIONS - Full Definitions: field.

INDEPENDENT CLAIMS are included for:

(1) a pharmaceutical composition (II) comprising (I) or its salt; and

(2) the identification of intestinotrophic analogs of GLP-2, comprising:

(i) obtaining a GLP-2 analog;

(ii) administration of the analog to a mammal via a regimen which elicits an intestinotrophic when utilized for rat GLP-2; and

(iii) determining the effect of the analog on the small bowel weight relative to a mock treated control mammal, whereby an intestinotrophic analog of GLP-2 elicits an increase in small bowel weight.

ACTIVITY - Antiulcer; antiinflammatory. CD1 mice were injected subcutaneously, twice a day with 2.5 mu g of glucagon-like peptide 2

(GLP-2) analog in a total volume of 0.5 cc of phosphate buffered saline (PBS). Animals were sacrificed 10 or 14 days after injection and were fasted at least 20 hours before sacrifice. The mice were anesthetized and exsanguinated by cardiac puncture. Blood was collected, centrifuged and the plasma was stored. The small bowel was removed from the peritoneal cavity, from pylorus to cecum, cleaned weighed and measured. Each small bowel fragment was opened longitudinally on its antimesenteric border in a tissue block and then placed on 10% formalin. Percentage change in small bowel weight was calculated by dividing the mean change in bowel weight of analog treated mice, relative to mice treated with vehicle only, by the mean bowel weight of mice treated with vehicle only and multiplying this figure by 100. The results showed that analogs of GLP-2 molecules have enhanced intestinotrophic activity.

MECHANISM OF ACTION - Analog of GLP-2 (claimed).

USE - (I) and (II) are useful for promoting the growth of small bowel tissue in a patient, to treat gastrointestinal disease such as ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hypo gamma globulinemic sprue, enteritis, regional enteritis (Crohn's disease), small intestinal damage due to toxic or chemotherapeutic agents, and short bowel syndrome, and to reduce a pathological effect or symptom of the gastrointestinal disease. (I) is useful for identifying intestinotrophic analogs of GLP-2 by obtaining (I), administering (I) to a mammal using a regimen capable of eliciting an intestinotrophic effect when utilized for rat GLP-2 and determining the effect of (I) on small bowel weight relative to a mock treated control animal, where (I) is identified as an analog which elicits an increase in the weight (claimed).

Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B04-C01G; B14-C03; B14-E08; B14-E10; B14-E11

L4 ANSWER 5 OF 5 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1996-477073 [47] WPIX
CR 1997-526401 [48]; 2001-217796 [22]; 2001-595776 [67]; 2003-787348 [74]; 2004-096715 [10]
DNC C1996-149012
TI Use of glucagon-like peptide-2 and analogues - for promoting growth and proliferation of gastrointestinal tissue, partic. for treating diseases.
DC B04
IN DRUCKER, D J; CRIVICI, A E; SUMNER-SMITH, M
PA (ONEO-N) 1149336 ONTARIO INC; (ONEO-N) 114336 ONTARIO INC; (ALLX) ALLELIX BIOPHARMACEUTICALS INC
CYC 71
PI WO 9632414 A1 19961017 (199647)* EN 55 C07K014-605
RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG
W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN
AU 9652658 A 19961030 (199708)
EP 830377 A1 19980325 (199816) EN
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 5789379 A 19980804 (199838) A61K038-00
US 5834428 A 19981110 (199901) A61K038-00
JP 11505521 W 19990521 (199931) 53 C07K014-605
US 5990077 A 19991123 (200002) A61K038-00 <--
MX 9707949 A1 19980601 (200009) C07K014-605
AU 720493 B 20000601 (200035)
CN 1188485 A 19980722 (200270) C07K014-605
ADT WO 9632414 A1 WO 1996-CA232 19960412; AU 9652658 A AU 1996-52658 19960412; EP 830377 A1 EP 1996-908973 19960412, WO 1996-CA232 19960412; US 5789379 A **Cont of US 1995-422540 19950414**, Cont of US 1996-631273 19960412, **Cont of US 1996-632533 19960412**, US 1996-669791 19960628; US 5834428 A **CIP of US 1995-422540 19950414, Cont of US**

1996-632533 19960412, US 1996-669790 19960628; JP 11505521 W JP 1996-530606 19960412, WO 1996-CA232 19960412; US 5990077 A **US 1995-422540 19950414**; MX 9707949 A1 MX 1997-7949 19971014; AU 720493 B AU 1996-52658 19960412; CN 1188485 A CN 1996-194693 19960412

FDT AU 9652658 A Based on WO 9632414; EP 830377 A1 Based on WO 9632414; JP 11505521 W Based on WO 9632414; AU 720493 B Previous Publ. AU 9652658, Based on WO 9632414

PRAI **US 1995-422540 19950414**; US 1996-631273 19960412; **US 1996-632533 19960412**; US 1996-669791 19960628; US 1996-669790 19960628

IC ICM A61K038-00; C07K014-605
ICS A61K038-26; C07K005-00; C07K007-00; C07K017-00

AB WO 9632414 A UPAB: 20040210
Novel pharmaceutical compsn., comprises a glucagon like peptide-2 (GLP-2) selected from a vertebrate GLP-2, or an intestinotrophic analogue, which differs from a vertebrate GLP-2 in that it incorporates at least 1 amino acid addition, deletion or substitution, or an amino acid with an N- or C-terminal amino acid blocking gp., and a carrier.

USE - The prods. and methods are used to promote the growth and proliferation of GI tissue. Specifically the compsn. can be used in the treatment of diabetes, or a GI disease, i.e. ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hyopgammaglobulinemic sprue, enteritis, regional enteritis (Crohn's diseases), small intestinal damage due to toxic or other chemotherapeutic agents or short bowel syndrome (claimed).

Dwg.0/9

FS CPI
FA AB
MC CPI: B04-C01; B04-N02; B14-E10; B14-N17B

=> b home
FILE 'HOME' ENTERED AT 17:08:33 ON 14 OCT 2005

=>